Tumor promoting role of anti-tumor macrophages in tumor microenvironment

Cellular Immunology

Volumn 316, Issue , 2017, Pages 1-10

  Goswami, Kuntal Kanti ^a   Ghosh, Tithi ^a   Ghosh, Sarbari ^a   Sarkar, Madhurima ^a   Bose, Anamika ^a   Baral, Rathindranath ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

Author keywords

Immune response; M1 M2; Macrophages; Tumor; Tumor microenvironment

Indexed keywords

ANGIOGENESIS INHIBITOR; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; GROWTH FACTOR; PEPTIDE; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; CANCER LOCALIZATION; CELL INFILTRATION; CELL INVASION; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; ENVIRONMENTAL FACTOR; HUMAN; HYPOXIA; IMMUNE RESPONSE; MACROPHAGE; METASTASIS; MONOCYTE; NECROSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POLARIZATION; PRIORITY JOURNAL; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; ANIMAL; IMMUNOLOGY; IMMUNOMODULATION; MOLECULARLY TARGETED THERAPY; MOUSE; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR ESCAPE;

ANIMALS; HUMANS; IMMUNOMODULATION; MACROPHAGES; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85017513021     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2017.04.005     Document Type: Review

References (83)

1. Nathan, C., Metchnikoff's legacy in. Nat. Immunol. 9:2008 (2008), 695–698.
2. Mosser, D.M., Edwards, J.P., Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8 (2008), 958–969.
3. Biswas, S.K., Sica, A., Lewis, C.E., Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J. Immunol. 180 (2008), 2011–2017.
4. Kelly, P.M., Davison, R.S., Bliss, E., McGee, J.O., Macrophages in human breast disease: a quantitative immunohistochemical study. Br. J. Cancer 57 (1988), 174–177.
5. Chakraborty, K., Bose, A., Pal, S., Sarkar, K., Goswami, S., Ghosh, D., et al. Neem leaf glycoprotein restores the impaired chemotactic activity of peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients by maintaining CXCR3/CXCL10 balance. Int. Immunopharmacol. 8 (2008), 330–340.
6. Siveen, K.S., Kuttan, G., Role of macrophages in tumour progression. Immunol. Lett. 123 (2009), 97–102.
7. Dalton, D.K., Pitts-Meek, S., Keshav, S., Figari, I.S., Bradley, A., Stewart, T.A., Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259 (1993), 1739–1742.
8. Mantovani, A., Biswas, S.K., Galdiero, M.R., Sica, A., Locati, M., Macrophage plasticity and polarization in tissue repair and remodeling. J. Pathol. 229 (2013), 176–185.
9. Gordon, S., Taylor, P.R., Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5 (2005), 953–964.
10. Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., Locati, M., The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25 (2004), 677–686.
11. Murdoch, C., Giannoudis, A., Lewis, C.E., Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104 (2004), 2224–2234.
12. Kovaleva, O.V., Samoilova, D.V., Shitova, M.S., Gratchev, A., Tumor associated macrophages in kidney cancer. Anal. Cell Pathol., 2016 Epub.
13. Ugel, S., De Sanctis, F., Mandruzzato, S., Bronte, V., Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J. Clin. Invest. 125 (2015), 3365–3376.
14. Murdoch, C., Muthana, M., Coffelt, S.B., Lewis, C.E., The role of myeloid cells in the promotion of tumor angiogenesis. Nat. Rev. Cancer 8 (2008), 618–631.
15. Locati, M., Deuschle, U., Massardi, M.L., Martinez, F.O., Sironi, M., Sozzani, S., et al. Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J. Immunol. 168 (2002), 3557–3562.
16. Gerszten, R.E., Garcia-Zepeda, E.A., Lim, Y.C., Yoshida, M., Ding, H.A. Jr., Gimbrone, M.A., MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398 (1999), 718–723.
17. Chakraborty, T., Bose, A., Goswami, K.K., Goswami, S., Chakraborty, K., Baral, R., Neem leaf glycoprotein suppresses regulatory T cell mediated suppression of monocyte/macrophage functions. Int. Immunopharmacol. 12 (2012), 326–333.
18. Wynn, T.A., Chawla, A., Pollard, J.W., Macrophage biology in development, homeostasis and disease. Nature 496 (2013), 445–455.
19. Lin, E.Y., Nguyen, A.V., Russell, R.G., Pollard, J.W., Colony stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193 (2001), 727–740.
20. Leek, R.D., Landers, R.J., Harris, A.L., Lewis, C.E., Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br. J. Cancer 79 (1999), 991–995.
21. Hiratsuka, S., Minowa, O., Kuno, J., Noda, T., Shibuya, M., Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. U S A. 95 (1998), 9349–9354.
22. Grant, K., Loizidou, M., Taylor, I., Endothelin-1: a multifunctional molecule in cancer. Br. J. Cancer 88 (2003), 163–166.
23. Grimshaw, M.J., Hagemann, T., Ayhan, A., Gillett, C.E., Binder, C., Balkwill, F.R., A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res. 64 (2004), 2461–2468.
24. Calandra, T., Bernhagen, J., Mitchell, R.A., Bucala, R., The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. 179 (1994), 1895–1902.
25. Overmeiere, E.V., Laoui, D., Keirsse, J., Ginderachter, J.V., Hypoxia and tumor associated macrophages: a deadly alliance in support of tumor progression. Oncoimmunology, 3, 2014, e27561.
26. Laoui, D., Overmeiere, E.V., Di Conza, G., Aldeni, C., Keirsse, J., Morias, Y., et al. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res. 74 (2014), 24–30.
27. Goswami, K.K., Sarkar, M., Ghosh, S., Saha, A., Ghosh, T., Guha, I., et al. Neem leaf glycoprotein regulates function of tumor associated M2 macrophages in hypoxic tumor core: Critical role of IL-10/STAT3 signaling. Mol. Immunol. 80 (2016), 1–10.
28. Butcher, E.C., Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 67 (1991), 1033–1036.
29. Muller, W.A., Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol. 24 (2003), 327–334.
30. Biswas, S.K., Mantovani, A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11 (2010), 889–896.
31. DeNardo, D.G., Barreto, J.B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N., et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16 (2009), 91–102.
32. Zaynagetdinov, R., Sherrill, T.P., Polosukhin, V.V., Han, W., Ausborn, J.A., McLoed, A.G., et al. A critical role for macrophages in promotion of urethane-induced lung carcinogenesis. J. Immunol. 187 (2011), 5703–5711.
33. Jiang, H., Harris, M.B., Rothman, P., IL-4/IL-13 signaling beyond JAK/STAT. J. Allergy Clin. Immunol. 105 (2000), 1063–1070.
34. Kambayashi, T., Alexander, H.R., Fong, M., Strassmann, G., Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J. Immunol. 154 (1995), 3383–3390.
35. Goswami, K.K., Barik, S., Banerjee, S., Bhowmick, A.K., Biswas, J., Bose, A., et al. Supraglottic laryngeal tumor microenvironmental factors facilitate STAT3 dependent pro-tumorigenic switch in tumor associated macrophages to render utmost immune evasion. Immunol. Lett. 156 (2013), 7–17.
36. Lang, R., Patel, D., Morris, J.J., Rutschman, R.L., Murray, P.J., Shaping gene expression in activated and resting primary macrophages by IL-10. J. Immunol. 169 (2002), 2253–2263.
37. Goswami, K.K., Barik, S., Sarkar, M., Bhowmick, A., Biswas, J., Bose, A., et al. Targeting STAT3 phosphorylation by neem leaf glycoprotein prevents immune evasion exerted by supraglottic laryngeal tumor induced M2 macrophages. Mol. Immunol. 59 (2014), 119–127.
38. Imtiyaz, H.Z., Williams, E.P., Hickey, M.M., Patel, S.A., Durham, A.C., Yuan, L.J., et al. Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J. Clin. Invest. 120 (2010), 2699–2714.
39. Ceradini, D.J., Kulkarni, A.R., Callaghan, M.J., Tepper, O.M., Bastidas, N., Kleinman, M.E., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10 (2004), 858–864.
40. Yoshimura, A., Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 97 (2006), 439–447.
41. O'Shea, J.J., Pesu, M., Borie, D.C., Changelian, P.S., A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat. Rev. Drug Discov. 3 (2004), 555–564.
42. Mantovani, A., Sozzani, S., Locati, M., Allavena, P., Sica, A., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23 (2002), 549–555.
43. Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multi component antitumor immunity. Nat. Med. 11 (2005), 1314–1321.
44. Sinha, P., Clements, V.K., Ostrand-Rosenberg, S., Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174 (2005), 636–645.
45. Langowski, J.L., Zhang, X., Wu, L., Mattson, J.D., Chen, T., Smith, K., et al. IL-23 promotes tumor incidence and growth. Nature 442 (2006), 461–465.
46. Condeelis, J., Pollard, J.W., Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124 (2006), 263–266.
47. Pollard, J.W., Tumor-educated macrophages promote tumor progression and metastasis. Nat. Rev. Cancer 4 (2004), 71–78.
48. Leek, R.D., Lewis, C.E., Whitehouse, R., Greenall, M., Clarke, J., Harris, A.L., Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56 (1996), 4625–4629.
49. Lewis, C.E., Leek, R., Harris, A., McGee, J.O., Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J. Leukoc. Biol. 57 (1995), 747–751.
50. Lin, L., Chen, Y.S., Yao, Y.D., Chen, J.Q., Chen, J.N., Huang, S.Y., et al. CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer. Oncotarget 6 (2015), 34758–34773.
51. Sica, A., Schioppa, T., Mantovani, A., Allavena, P., Tumour associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42 (2006), 717–727.
52. Ito, M., Minamiya, Y., Kawai, H., Saito, S., Saito, H., Nakagawa, T., et al. Tumor-derived TGFβ-1 induces dendritic cell apoptosis in the sentinel lymph node. J. Immunol. 176 (2006), 5637–5643.
53. Thomas, D.A., Massagu'e, J., TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8 (2005), 369–380.
54. Sun, Z., Yao, Z., Liu, S., Tang, H., Yan, X., An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer. Immunobiology 211 (2006), 199–209.
55. Solinas, G., Germano, G., Mantovani, A., Allavena, P., Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 86 (2009), 1065–1073.
56. Dvorak, H.F., Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315 (1986), 1650–1659.
57. Coussens, L.M., Tinkle, C.L., Hanahan, D., Werb, Z., MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103 (2000), 481–490.
58. Hagemann, T., Wilson, J., Kulbe, H., Li, N.F., Leinster, D.A., Charles, K., et al. Macrophages induce invasiveness of epithelial cancer cells via NF-κ B and JNK. J. Immunol. 175 (2005), 1197–1205.
59. Gorelik, E., Wiltrout, R.H., Brunda, M.J., Augmentation of metastasis formation by thioglycollate-elicited macrophages. Int. J. Cancer 29 (1982), 575–581.
60. Coffelt, S.B., Hughes, R., Lewis, C.E., Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim. Biophys. Acta 1796 (2009), 11–18.
61. Lynch, C.C., Hikosaka, A., Acuff, H.B., Martin, M.D., Kawai, N., Singh, R.K., et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 7 (2005), 485–496.
62. Yang, M., Chen, J., Su, F., Yu, B., Su, F., Lin, L., et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol. Cancer, 10, 2011, 117.
63. Kim, S., Takahashi, H., Lin, W.W., Descargues, P., Grievennikov, S., Kim, Y., et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457 (2009), 102–106.
64. Robinson, S.C., Scott, K.A., Wilson, J.L., Thompson, R.G., Proudfoot, A.E., Balkwill, F.R., A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res. 63 (2003), 8360–8365.
65. El-Gamal, M.I., Anbar, H.S., Yoo, K.H., Oh, C.H., FMS kinase inhibitors: current status and future prospects. Med. Res. Rev. 33 (2013), 599–636.
66. Yin, M., Li, X., Tan, S., Zhou, H.J., Ji, W., Bellone, S., et al. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J. Clin. Invest. 126 (2016), 4157–4173.
67. Arts, R.J., Plantinga, T.S., Tuit, S., Ulas, T., Heinhuis, B., Tesselaar, M., et al. Transcriptional and metabolic reprogramming induce an inflammatory phenotype in non-medullary thyroid carcinoma-induced macrophages. Oncoimmunology, 5, 2016, e1229725.
68. Sessa, C., De Braud, F., Perotti, A., Bauer, J., Curigliano, G., Noberasco, C., et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J. Clin. Oncol. 23 (2005), 1867–1874.
69. Zhang, W., Zhu, X.D., Sun, H.C., Xiong, Y.Q., Zhuang, P.Y., Xu, H.X., et al. Depletion of tumor associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin. Cancer Res. 16 (2010), 3420–3430.
70. Vukanovic, J., Isaacs, J.T., Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res. 55 (1995), 1499–1504.
71. Xiang, R., Luo, Y., Niethammer, A.G., Reisfeld, R.A., Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis. Immunol. Rev. 222 (2008), 117–128.
72. Faham, N., Welm, A.L., RON Signaling Is a key mediator of tumor progression in many human cancers. Cold Spring Harb. Symp. Quant. Biol., 2017 Jan 5, [Epub ahead of print].
73. Zeisberger, S.M., Odermatt, B., Marty, C., Zehnder-Fjallman, A.H., Ballmer-Hofer, K., et al. Clodronate-liposome mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer 95 (2006), 272–281.
74. Priceman, S.J., Sung, J.L., Shaposhnik, Z., Burton, J.B., Torres-Collado, A.X., Moughon, D.L., et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 115 (2010), 1461–1471.
75. Srivastava, K., Hu, J., Korn, C., Savant, S., Teichert, M., Kapel, S.S., et al. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell 26 (2014), 880–895.
76. Banerjee, S., Ghosh, T., Barik, S., Das, A., Ghosh, S., Bhuniya, A., et al. Neem leaf glycoprotein prophylaxis transduces immune dependent stop signal for tumor angiogenic switch within tumor microenvironment. PLoS ONE, 9, 2014, e110040.
77. Guiducci, C., Vicari, A.P., Sangaletti, S., Trinchieri, G., Colombo, M.P., Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65 (2005), 3437–3446.
78. Rauh, M.J., Sly, L.M., Kalesnikoff, J., Hughes, M.R., Cao, L.P., Lam, V., et al. The role of SHIP1 in macrophage programming and activation. Biochem. Soc. Trans. 32 (2004), 785–788.
79. Ong, C.J., Ming-Lum, A., Nodwell, M., Ghanipor, A., Yang, L., Williams, D.E., et al. Small molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Blood 110 (2007), 1942–1949.
80. Muller, A.J., DuHadaway, J.B., Donover, P.S., Sutanto-Ward, E., Prendergast, G.C., Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11 (2005), 312–319.
81. Cullis, J.E., Siolas, D., Avanzi, A., Barui, S., Maitra, A., Bar-Sagi, D., Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer. Cancer Immunol Res., 2017 [Epub ahead of print].
82. Oronsky, B., Paulmurugan, R., Foygel, K., Scicinski, J., Knox, S.J., Peehl, D., et al. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opin. Investig. Drugs 26 (2017), 109–119.
83. Ye, X., Zhang, J., Lu, R., Zhou, G., Signal regulatory protein α associated with the progression of oral leukoplakia and oral squamous cell carcinoma regulates phenotype switch of macrophages. Oncotarget 7 (2016), 81305–81321.